Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model

Michael Haley, Chantai Parent, Xizhong Cui, Andre C Kalil, Yvonne Fitz, Rosaly Correa-Araujo, Charles Natanson, Robert L. Danner, Steven M. Banks, Peter Q. Eichacker

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Both route and severity of infection may influence immunomodulator agents in sepsis. We studied the effect of each variable on HRL-3, an L-selectin-directed MAb that inhibits neutrophil function, in a rat sepsis model. Animals (n = 800) were randomized to be treated with either HRL-3 or placebo and to receive Escherichia coli either intravenously (IV) or intrabronchially (IB) in doses producing low or high mortality rates. Animals received antibiotics and were observed for 168 h. Route but not dose of E. coli altered the effects HRL-3 on mortality rate (mean hazards ratio ± SE). With IV E. coli, compared with control, HRL-3 was beneficial and reduced the hazards ratio both early (0 to 6 h; -0.75 ± 0.23) and late (6 to 168 h; -0.72 ± 0.36) (P = 0.001 and 0.04, respectively, over all E. coli doses). In contrast, with IB E. coli HRL-3 reduced the hazards ratio early (-1.1 ± 0.36) but worsened it late (0.87 ± 0.23) (P = 0.002 for both effects over all E. coli doses) in patterns significantly different from IV E. coli (P < 0.0001). Compared with control, although HRL-3 did not alter lung neutrophil numbers or injury score at 6 or 168 h with IV E. coli (P = ns for all), it reduced both early and increased them late with IB. E. coli (P ≤ 0.05 for all comparing 6 with 168 h). Thus immunomodulators inhibiting neutrophil function, although potentially beneficial with sepsis due to intravascular infection, may be harmful with extravascular infection regardless of severity.

Original languageEnglish (US)
Pages (from-to)2155-2162
Number of pages8
JournalJournal of Applied Physiology
Volume98
Issue number6
DOIs
StatePublished - Jun 1 2005

Fingerprint

L-Selectin
Sepsis
Neutrophils
Escherichia coli
Infection
Immunologic Factors
Mortality
Placebos
Anti-Bacterial Agents
Lung

Keywords

  • Adhesion
  • Shock
  • Treatment

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. / Haley, Michael; Parent, Chantai; Cui, Xizhong; Kalil, Andre C; Fitz, Yvonne; Correa-Araujo, Rosaly; Natanson, Charles; Danner, Robert L.; Banks, Steven M.; Eichacker, Peter Q.

In: Journal of Applied Physiology, Vol. 98, No. 6, 01.06.2005, p. 2155-2162.

Research output: Contribution to journalArticle

Haley, Michael ; Parent, Chantai ; Cui, Xizhong ; Kalil, Andre C ; Fitz, Yvonne ; Correa-Araujo, Rosaly ; Natanson, Charles ; Danner, Robert L. ; Banks, Steven M. ; Eichacker, Peter Q. / Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. In: Journal of Applied Physiology. 2005 ; Vol. 98, No. 6. pp. 2155-2162.
@article{b30de0acf0e4410fbf9ee86cc65b01ab,
title = "Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model",
abstract = "Both route and severity of infection may influence immunomodulator agents in sepsis. We studied the effect of each variable on HRL-3, an L-selectin-directed MAb that inhibits neutrophil function, in a rat sepsis model. Animals (n = 800) were randomized to be treated with either HRL-3 or placebo and to receive Escherichia coli either intravenously (IV) or intrabronchially (IB) in doses producing low or high mortality rates. Animals received antibiotics and were observed for 168 h. Route but not dose of E. coli altered the effects HRL-3 on mortality rate (mean hazards ratio ± SE). With IV E. coli, compared with control, HRL-3 was beneficial and reduced the hazards ratio both early (0 to 6 h; -0.75 ± 0.23) and late (6 to 168 h; -0.72 ± 0.36) (P = 0.001 and 0.04, respectively, over all E. coli doses). In contrast, with IB E. coli HRL-3 reduced the hazards ratio early (-1.1 ± 0.36) but worsened it late (0.87 ± 0.23) (P = 0.002 for both effects over all E. coli doses) in patterns significantly different from IV E. coli (P < 0.0001). Compared with control, although HRL-3 did not alter lung neutrophil numbers or injury score at 6 or 168 h with IV E. coli (P = ns for all), it reduced both early and increased them late with IB. E. coli (P ≤ 0.05 for all comparing 6 with 168 h). Thus immunomodulators inhibiting neutrophil function, although potentially beneficial with sepsis due to intravascular infection, may be harmful with extravascular infection regardless of severity.",
keywords = "Adhesion, Shock, Treatment",
author = "Michael Haley and Chantai Parent and Xizhong Cui and Kalil, {Andre C} and Yvonne Fitz and Rosaly Correa-Araujo and Charles Natanson and Danner, {Robert L.} and Banks, {Steven M.} and Eichacker, {Peter Q.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1152/japplphysiol.01241.2004",
language = "English (US)",
volume = "98",
pages = "2155--2162",
journal = "Journal of Applied Physiology",
issn = "0161-7567",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model

AU - Haley, Michael

AU - Parent, Chantai

AU - Cui, Xizhong

AU - Kalil, Andre C

AU - Fitz, Yvonne

AU - Correa-Araujo, Rosaly

AU - Natanson, Charles

AU - Danner, Robert L.

AU - Banks, Steven M.

AU - Eichacker, Peter Q.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Both route and severity of infection may influence immunomodulator agents in sepsis. We studied the effect of each variable on HRL-3, an L-selectin-directed MAb that inhibits neutrophil function, in a rat sepsis model. Animals (n = 800) were randomized to be treated with either HRL-3 or placebo and to receive Escherichia coli either intravenously (IV) or intrabronchially (IB) in doses producing low or high mortality rates. Animals received antibiotics and were observed for 168 h. Route but not dose of E. coli altered the effects HRL-3 on mortality rate (mean hazards ratio ± SE). With IV E. coli, compared with control, HRL-3 was beneficial and reduced the hazards ratio both early (0 to 6 h; -0.75 ± 0.23) and late (6 to 168 h; -0.72 ± 0.36) (P = 0.001 and 0.04, respectively, over all E. coli doses). In contrast, with IB E. coli HRL-3 reduced the hazards ratio early (-1.1 ± 0.36) but worsened it late (0.87 ± 0.23) (P = 0.002 for both effects over all E. coli doses) in patterns significantly different from IV E. coli (P < 0.0001). Compared with control, although HRL-3 did not alter lung neutrophil numbers or injury score at 6 or 168 h with IV E. coli (P = ns for all), it reduced both early and increased them late with IB. E. coli (P ≤ 0.05 for all comparing 6 with 168 h). Thus immunomodulators inhibiting neutrophil function, although potentially beneficial with sepsis due to intravascular infection, may be harmful with extravascular infection regardless of severity.

AB - Both route and severity of infection may influence immunomodulator agents in sepsis. We studied the effect of each variable on HRL-3, an L-selectin-directed MAb that inhibits neutrophil function, in a rat sepsis model. Animals (n = 800) were randomized to be treated with either HRL-3 or placebo and to receive Escherichia coli either intravenously (IV) or intrabronchially (IB) in doses producing low or high mortality rates. Animals received antibiotics and were observed for 168 h. Route but not dose of E. coli altered the effects HRL-3 on mortality rate (mean hazards ratio ± SE). With IV E. coli, compared with control, HRL-3 was beneficial and reduced the hazards ratio both early (0 to 6 h; -0.75 ± 0.23) and late (6 to 168 h; -0.72 ± 0.36) (P = 0.001 and 0.04, respectively, over all E. coli doses). In contrast, with IB E. coli HRL-3 reduced the hazards ratio early (-1.1 ± 0.36) but worsened it late (0.87 ± 0.23) (P = 0.002 for both effects over all E. coli doses) in patterns significantly different from IV E. coli (P < 0.0001). Compared with control, although HRL-3 did not alter lung neutrophil numbers or injury score at 6 or 168 h with IV E. coli (P = ns for all), it reduced both early and increased them late with IB. E. coli (P ≤ 0.05 for all comparing 6 with 168 h). Thus immunomodulators inhibiting neutrophil function, although potentially beneficial with sepsis due to intravascular infection, may be harmful with extravascular infection regardless of severity.

KW - Adhesion

KW - Shock

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=21144451354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144451354&partnerID=8YFLogxK

U2 - 10.1152/japplphysiol.01241.2004

DO - 10.1152/japplphysiol.01241.2004

M3 - Article

VL - 98

SP - 2155

EP - 2162

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 0161-7567

IS - 6

ER -